10-Q: Agentix Corp. Faces Going Concern Doubts Amid Rising Losses

Agentix Corp. reported increased net losses and negative operating cash flow, raising substantial doubt about its ability to continue as a going concern.

Summary

• Agentix Corp. reported a net loss of $144,107 for the three months ended September 30, 2025, compared to $90,669 for the same period in 2024.
• For the six months ended September 30, 2025, the net loss was $329,931, an increase from $241,386 in the prior year.
• The company had only $5,601 in cash as of September 30, 2025, and a total stockholders' deficit of $3,418,038.
• Operating expenses for the six months ended September 30, 2025, increased to $323,439 from $244,315 in the prior year, driven by higher professional fees and research and development costs.
• Cash flows from operating activities were negative $115,367 for the six months ended September 30, 2025, a significant decline from positive $4,979 in the prior year.
• Total current liabilities increased to $3,423,639 as of September 30, 2025, from $3,204,523 as of March 31, 2025.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, including a going concern warning, critically low cash, increasing losses, negative operating cash flow, and ineffective disclosure controls. The outlook for securing necessary financing is uncertain, with a high risk of business failure.

Positives

• General and administrative expenses for the six months ended September 30, 2025, decreased slightly to $34,502 from $35,654 in the prior year, reflecting cost controls.

Negatives

• Substantial doubt exists about the ability to continue as a going concern due to an accumulated deficit, net losses, negative cash flows from operating activities, and negative working capital.
• Net loss increased to $144,107 for the three months ended September 30, 2025, from $90,669 in the prior year.
• Net loss for the six months ended September 30, 2025, increased to $329,931 from $241,386 in the prior year.
• Cash on hand is critically low at $5,601 as of September 30, 2025.
• Negative cash flows from operating activities of $115,367 for the six months ended September 30, 2025, a significant deterioration from the prior year's positive cash flow.
• Total current liabilities increased to $3,423,639, with significant amounts owed to related parties ($2,258,947 in accounts payable and $343,350 in notes payable).
• Disclosure controls and procedures were not effective as of September 30, 2025.
• Interest expense, net, significantly increased to $45,385 for the six months ended September 30, 2025, from $17,479 in the prior year, reflecting higher average borrowings and related financing costs.
• Total current assets decreased significantly from $100,274 as of March 31, 2025, to $5,601 as of September 30, 2025, primarily due to the utilization of prepaid expenses.

Risks

• Substantial doubt about the ability to continue as a going concern due to accumulated deficit, net losses, negative cash flows from operating activities, and negative working capital.
• Inability to obtain additional financing to support daily operations and fund the business plan for the next 12 months.
• Potential for significant dilution for existing shareholders if equity financing is pursued.
• Risk of business failure if sufficient financing cannot be secured.
• Ineffective disclosure controls and procedures, which could lead to material misstatements or failures in financial reporting.
• Dependence on related party financing, which may not be sustainable or on favorable terms.
• The company operates in the clinical-stage biotechnology sector, which inherently involves high R&D costs and no current revenue generation.

Future Outlook

The company's cash position is not sufficient to support daily operations, and it will need further funding to implement its business plan and cover ongoing operational expenses for the next 12 months. Additional funding is expected to come from equity or debt financing, with a warning of potential dilution for existing shareholders and the risk of business failure if financing is not secured.

Management Comments

• Management has included projections and estimates in this Form 10-Q, which are based primarily on management's experience in the industry, assessments of results of operations, discussions and negotiations with third parties and a review of information filed by competitors with the SEC or otherwise publicly available.
• Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. Management disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
• Our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective as of September 30, 2025.

Industry Context

Agentix Corp. operates as a clinical-stage biotechnology company, a sector characterized by high research and development costs, long development cycles, and significant capital requirements before potential revenue generation. The company's current financial state, marked by zero revenue, increasing losses, and a critical cash shortage, is not uncommon for early-stage biotech firms. However, the explicit 'going concern' warning and ineffective disclosure controls highlight severe operational and financial challenges that could hinder its ability to advance its therapeutic agents for metabolic diseases like Type 2 diabetes, obesity, NAFLD, and NASH, an area with high unmet medical needs but also intense competition and regulatory hurdles.

Comparison to Industry Standards

• Agentix Corp.'s financial performance, with zero revenue and increasing net losses ($329,931 for six months), is significantly below the operational benchmarks of established biotechnology companies like Amgen or Gilead Sciences, which generate billions in revenue.
• Compared to other clinical-stage biotech companies, Agentix's cash position of $5,601 is extremely low, indicating a severe liquidity crisis. Many early-stage biotechs typically maintain cash reserves sufficient for at least 12-18 months of operations to fund ongoing R&D and clinical trials.
• The reliance on related-party debt and advances, totaling over $2.6 million, suggests difficulty in securing traditional institutional financing, which is a common challenge for companies facing going concern issues.
• The disclosure of ineffective disclosure controls and procedures is a significant governance red flag, contrasting sharply with the robust internal controls expected of publicly traded companies, regardless of size. This could deter potential investors and partners.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any legal proceedings that, in the opinion of management, are likely to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• SBS Management LLC (controlled by a shareholder, Mr. Scott Stevens) received $206,387 in management consulting fees and advances for expenses for the six months ended September 30, 2025. The company owed SBS Management LLC $1,371,878 as of September 30, 2025, for unsecured, non-interest bearing advances with no formal repayment terms.
• Grays Peak Capital (founded by a shareholder) made advances to cover operating expenses. The company owed Grays Peak Capital $516,223 as of September 30, 2025, for unsecured, non-interest bearing advances with no formal repayment terms.
• Grays Peak Private Credit LLC (related to Grays Peak Capital) holds a Mezzanine Secured Note with a principal balance of $343,350 as of September 30, 2025. This note bears interest at 7.5% for 30 days, then 2% per month, and is secured by all company assets. The June 15, 2023 note was extended to December 31, 2025.
• Management was owed $433,497 as of September 30, 2025, included in accounts payable related parties.

Stakeholder Impact

• Shareholders face significant dilution risk from potential equity financing. The 'going concern' warning indicates a high risk of total loss of investment if financing is not secured. The stock price is highly likely to be negatively impacted.
• Creditors (especially related parties) face repayment uncertainty given the company's severe liquidity issues and going concern doubts. The secured note held by Grays Peak Private Credit LLC has priority over unsecured debt.
• Employees face potential job insecurity due to the company's financial instability and the risk of business failure.
• Customers/Partners: The company is clinical-stage with no revenue, so direct customer impact is minimal. However, potential partners for its therapeutic agents may be deterred by the financial instability.

Next Steps

• Raise additional funds through equity or debt financing to support operations and implement the business plan for the next 12 months.
• Address the identified ineffectiveness of disclosure controls and procedures.
• Continue development of therapeutic agents for metabolic diseases.

Key Dates

Recommendation

The company is in severe financial distress, explicitly stating 'substantial doubt about the Company's ability to continue as a going concern.' It has critically low cash ($5,601), increasing net losses, negative operating cash flow, and a growing accumulated deficit. The disclosure of ineffective internal controls further exacerbates the risk profile. While the company is a clinical-stage biotech, its current financial state and the uncertainty of securing future funding make it a highly speculative and high-risk investment, with a stated risk of business failure. Investors should consider exiting their positions to avoid further capital loss.

Keywords

Agentix Corp, AGTX, 10-Q, Quarterly Report, biotechnology, clinical-stage, metabolic disease, Type 2 diabetes, obesity, NAFLD, NASH, financial results, net loss, cash flow, going concern, liquidity, capital raise, related party transactions, disclosure controls, SEC filing